Celltrion Pharm Inc.

As of March 31, 2026, Celltrion Pharm Inc. carries a market capitalization of 2.43T, placing it among publicly traded companies globally. Its enterprise value stands at 2.45T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Celltrion Pharm Inc. has 44.26M shares outstanding.

As of March 31, 2026, Celltrion Pharm Inc. trades at a trailing price-to-earnings ratio of 60.31. The price-to-sales ratio is 4.37, and the price-to-book ratio stands at 5.58.

As of March 31, 2026, Celltrion Pharm Inc. trades at an EV/EBITDA multiple of 30.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 42.09 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Celltrion Pharm Inc. trades at an EV/FCF ratio of 42.70, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.45T versus a market cap of 2.43T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Celltrion Pharm Inc. maintains a current ratio of 1.65, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.93, indicating elevated leverage, while an interest coverage ratio of 12.55 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Celltrion Pharm Inc. posted a return on equity (ROE) of 9.62, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.65 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.57, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.76, useful for judging operating efficiency across full business cycles. The company generates approximately 604.35M in revenue per employee across its workforce of 920.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.35 indicates how many times Celltrion Pharm Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Celltrion Pharm Inc. recorded 11.81B in income tax expense. That works out to an effective tax rate of 22.69, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 52.06B, leaving 40.25B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Celltrion Pharm Inc.'s stock has declined approximately 32.24% over the past 52 weeks. The 50-day moving average sits at 40,386.00, while the 200-day moving average is 51,079.68.

Over the twelve months ended March 31, 2026, Celltrion Pharm Inc. generated 556.00B in revenue and converted that into 40.25B in net income, yielding earnings per share of 908.63. EBITDA reached 81.45B, while operating income came in at 58.26B.

As of March 31, 2026, Celltrion Pharm Inc. holds 133.91B in cash and equivalents against 160.58B in total debt, resulting in a net debt position of 85.21B. Total book value stands at 434.82B, with working capital of 188.86B providing operational flexibility.

Celltrion Pharm Inc. produced 77.88B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -25.47B in capital expenditures, free cash flow totaled 52.41B - equivalent to 1,183.31 per share.

Over the twelve months ended March 31, 2026, Celltrion Pharm Inc. posted a gross margin of 30.52, reflecting its pricing power and cost economics. The operating margin of 10.48 and net profit margin of 7.24 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 2.16, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Celltrion Pharm Inc. shareholders.

Celltrion Pharm Inc.'s most recent stock split took place on December 29, 2025 with a 50:51 split ratio.

As of March 31, 2026, Celltrion Pharm Inc. has an Altman Z-Score of 6.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.